BRNS (Barinthus Biotherapeutics plc American Depositary Shares) Stock Analysis - Insider Trades

Barinthus Biotherapeutics plc American Depositary Shares (BRNS) is a publicly traded Healthcare sector company. As of May 21, 2026, BRNS trades at $0.69 with a market cap of $26.08M and a P/E ratio of -0.42. BRNS moved +2.41% today. Year to date, BRNS is -5.52%; over the trailing twelve months it is -22.81%. Its 52-week range spans $0.51 to $2.92. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces BRNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BRNS stock inside the company?

Rallies tracks BRNS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.

BRNS Key Metrics

Key financial metrics for BRNS
MetricValue
Price$0.69
Market Cap$26.08M
P/E Ratio-0.42
EPS$-1.64
Dividend Yield0.00%
52-Week High$2.92
52-Week Low$0.51
Volume0
Avg Volume0
Revenue (TTM)$506.00K
Net Income$-66.46M
Gross Margin0.00%

Latest BRNS News

BRNS Analyst Consensus

1 analysts cover BRNS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.

Common questions about BRNS

Who is trading BRNS stock inside the company?
Rallies tracks BRNS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
Does Rallies show Form 4 insider transactions for BRNS?
Yes. Rallies tracks BRNS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BRNS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BRNS. It does not provide personalized investment advice.
BRNS

BRNS